ArticleThe pharmacogenomics journal2013
DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia.
Article in The pharmacogenomics journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway.Frontiers in neurology · 2024Pooled it
- The genetics of drug-related movement disorders, an umbrella review of meta-analyses.Molecular psychiatry · 2020Pooled it
- The role of DPP6 dysregulation in neuropathology: from synaptic regulation to disease mechanisms.Frontiers in cellular neuroscience · 2025Review
- Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic Treatments.Pharmaceutics · 2024Review
- Neuronal Roles of the Multifunctional Protein Dipeptidyl Peptidase-like 6 (DPP6).International journal of molecular sciences · 2022Review
- The Prevalence of Pharmacogenomics Variants and Their Clinical Relevance Among the Pakistani Population.Evolutionary bioinformatics online · 2022Article
- Genome wide study of tardive dyskinesia in schizophrenia.Translational psychiatry · 2021Article
- Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.Frontiers in pharmacology · 2021Review
- Population structure and pharmacogenomic risk stratification in the United States.BMC biology · 2020Article
- Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.International journal of molecular sciences · 2020Review
- Genetics of Common Antipsychotic-Induced Adverse Effects.Molecular neuropsychiatry · 2016Review
- Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.Clinical and experimental immunology · 2016Review
- Functional Evaluations of Genes Disrupted in Patients with Tourette's Disorder.Frontiers in psychiatry · 2016Review
- Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia.Journal of neural transmission (Vienna, Austria : 1996) · 2015Article
- Genetic Determinants of Pelvic Organ Prolapse among African American and Hispanic Women in the Women's Health Initiative.PloS one · 2015Article
- Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.Frontiers in neurology · 2015Review
- DPP6 gene disruption in a family with Gilles de la Tourette syndrome.Neurogenetics · 2014Article
- Genome-wide linkage analysis and association study identifies loci for polydactyly in chickens.G3 (Bethesda, Md.) · 2014Article
- Modulatory mechanisms and multiple functions of somatodendritic A-type K (+) channel auxiliary subunits.Frontiers in cellular neuroscience · 2014Review
- Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.Journal of molecular neuroscience : MN · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We implemented a two-step approach to detect potential predictor gene variants for neuroleptic-induced tardive dyskinesia (TD) in schizophrenic subjects. First, we screened associations by using a genome-wide (Illumina HumanHapCNV370) SNP array in 61 Japanese schizophrenia patients with treatment-resistant TD and 61 Japanese schizophrenia patients without TD. Next, we performed a replication analysis in 36 treatment-resistant TD and 138 non-TD subjects. An association of an SNP in the DPP6 (dipeptidyl peptidase-like protein-6) gene, rs6977820, the most promising association identified by the screen, was significant in the replication sample (allelic P=0.008 in the replication sample, allelic P=4.6 × 10(-6), odds ratio 2.32 in the combined sample). The SNP is located in intron-1 of the DPP6 gene and the risk allele was associated with decreased DPP6 gene expression in the human postmortem prefrontal cortex. Chronic administration of haloperidol increased Dpp6 expression in mouse brains. DPP6 is an auxiliary subunit of Kv4 and regulates the properties of Kv4, which regulates the activity of dopaminergic neurons. The findings of this study indicate that an altered response of Kv4/DPP6 to long-term neuroleptic administration is involved in neuroleptic-induced TD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.